Quality by Design in Generic Drug Development

Chair(s):
Sun, Z., Office of Generic Drugs, OPS, CDER, FDA
Co-chair(s):
Joshi, Y., Teva Pharmaceuticals

Due the highly competitive marketplace for generic drugs and rising customer demand (with 65-70% of prescriptions now filled with generic drugs), accelerating generic drug development and assuring the quality of generic drugs through the product life cycle is a critical challenge. Implementation of quality by design (QbD) in generic drug development can enhance understanding of raw materials, formulation design, and manufacturing parameters, and their impact on finished product quality, which will result in more efficient and robust manufacturing process as well as higher quality products. This session will invite scientists from both generic drug industries and regulatory agencies to discuss the current practices, challenges, and opportunities for QbD in generic drug development. It is intended to provide an open forum to explore how to facilitate QbD implementation in generic drug development.

Papers:
Topics: 

Checkout

Paper abstracts are public but to access Extended Abstracts, you must first purchase the conference proceedings.

Checkout

Do you already own this?

Pricing


Individuals

2010 Annual Meeting
AIChE Members $150.00
AIChE Graduate Student Members Free
AIChE Undergraduate Student Members Free
Non-Members $225.00
Comprehensive Quality by Design in Pharmaceutical Development and Manufacture only
AIChE Members $100.00
AIChE Food, Pharmaceutical & Bioengineering Division Members Free
AIChE Graduate Student Members Free
AIChE Undergraduate Student Members Free
Non-Members $150.00